在健康和疾病中的棕酸蛋白硫酶-1
Morgan Barnes1, Renuka Raman1, Sean Ekins1
1Collaborations Pharmaceuticals, Inc., 1730 Varsity Drive, Suite 360, Raleigh, NC, 27606-5228, USA.
Trends in pharmacological sciences
|February 25, 2026
概括
棕酸蛋白硫酶-1 (PPT1) 调节蛋白质功能,在像巴顿病这样的神经退行性疾病中至关重要. 对PPT1的研究为各种疾病提供了潜在的治疗点.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 神经科学是一个神经科学.
背景情况:
- 棕化/脱棕化循环对于细胞过程至关重要,包括信号转导和神经元活动.
- 棕酸蛋白硫酶-1 (PPT1) 是这个循环中的一个关键酶,它从蛋白质中去除棕酸基.
- PPT1的功能障碍与巴顿病 (CLN1) 等严重疾病有关,并对癌症和其他疾病有影响.
研究的目的:
- 为了提供一个全面的概述Palmitoyl-蛋白 thioesterase-1 (PPT1).
- 探索PPT1的结构,酶活性,基质和各种生物作用.
- 审查目前和正在开发的针对PPT1的治疗方法.
主要方法:
- 对PPT现有研究的文献综述1.
- 分析PPT1的生物化学特性和基质相互作用.
- 针对PPT1.1的临床前和临床药物开发的调查.
主要成果:
- 突出了PPT1在蛋白质调节中的关键作用及其在多种疾病病理中的参与.
- 该审查详细介绍了PPT1的结构,活性和已知的基质.
- 介绍了目前正在开发中的针对PPT1的药物.
结论:
- PPT1是一种重要的酶,在各种疾病中具有广泛的治疗潜力.
- 了解PPT1的功能和治疗场景对于未来的研究和药物开发至关重要.
- 尽管存在翻译方面的挑战,但PPT1仍然是新型治疗策略的有希望的目标.
相关概念视频
The Proteasome
10.4K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.4K
The Proteasome
1.9K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.9K
Protein Modifications in the RER
7.3K
Modification of secretory and transmembrane proteins entering the rough ER begins in the ER lumen. These modifications aid in protein folding and stabilize the acquired tertiary structure. Protein modifications in the rough ER co-occur at different stages of protein folding.
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
Broadly, these modifications can be categorized into four main categories — glycosylation, formation of disulfide bonds, assembly of protein subunits, and specific proteolytic cleavages like removal of signal...
7.3K
Regulated Protein Degradation
9.1K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
9.1K
Regulated Protein Degradation
3.3K
3.3K
Amyloid Fibrils
12.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.2K


